Aiming to improve the chances of all those affected.
Zugang zum PanTum Detect® Portal (nur für Krebs-Scan Kunden):
SIMPLE
A normal blood sample once a year is all it takes.
EARLY
Detection of tumor indicators in early, symptom-free stages.
GROUNDBREAKING
Prerequisite for targeted use of medical imaging (e.g. PET/CT, MRI).
ONE FOR ALLMOST ALL
A multi-cancer blood test for indications of almost all types of cancer.
PanTum Detect® is an in vitro diagnostic medical device as defined by Regulation (EU) 2017/746 (IVDR). The conformity assessment was conducted by the Notified Body TÜV Rheinland LGA Products GmbH.
This is based on the certificate for the quality management system in accordance with IVDR Annex IX, Chapter I, as well as the assessment of the technical documentation in accordance with Annex IX, Chapter II, issued in July 2026. PanTum Detect® bears the CE marking with the Notified Body’s identification number (CE 0197).
NEED FOR EARLY CANCER DETECTION
In the majority of cases, cancer grows undetected for many years. The earlier it is detected, the better the chances of a complete recovery.
EVERY 2ND PERSON
DEVELOPS CANCER
Statistically, about every other person develops cancer once in his or her life.
Source: Cancer Research UK
CANCER-SPECIFIC
SCREENING
Regular cancer-specific screening examinations exist in selected countries for breast, cervical, colorectal, lung, prostate, and skin cancer.
Source: German Cancer Research Center; American Cancer Society
SCREENING GAP
CASE: GERMANY
Even in a medically advanced country such as Germany, for 55% of the 500k annual new cancer cases, no regular screening examinations exist. That amounts to more than 250k cases every year.
Source: average yearly new cancer cases based on data of RKI (krebsdaten.de |2009-2018)
PANTUM DETECT® – DEVELOPED TO MAKE A DIFFERENCE
- Can give early indications for potential tumors, at a time when treatment options are manifold and chances of cure are high.
- Developed to detect indications at the right time and stage – not too early, not too late.
- Using a single blood sample once a year.
- Not cancer type specific: Applies to almost all types of cancer that can be traced back to solid tumors.
- Detects signals for two biophyscial mechanisms that all types of cancer have in common.
- PanTum Detect® does not diagnose cancer or identify types of cancer, it gives general indications that need to be confirmed and localized in follow-up diagnostics, such as imaging procedures.
WHO IS PANTUM DETECT® FOR?
For anyone, who …
… wants to do more for their health.
… has a family history of cancer.
… does not want to wait until it might be too late.
… looks for a perfect addition to the already existing regular cancer screening examinations.
To see whether cancer screening makes sense for you individually given your current personal situation (age, family medical history, personal medical history, personal medical condition, etc.), please consult your physician.
WHAT IS THE INTENDED USE?
The PanTum Detect® alone does not provide cancer diagnosis. It provides indications of elevated concentrations of DNaseX (Apo10) and TKTL1 in human EDTA whole blood. The qualitative test result identifies persons with increased glucose uptake and decreased apoptosis. Positive results can be associated with a possible tumor development, but do not rule out other underlying pathological changes. The test is intended to be used in the context of the preventive medical checkup. Persons with a positive result will be examined using suitable medical imaging techniques.
PanTum Detect® cannot replace recommended early detection/preventive examinations, but rather supplements them. We generally advise continuing to take advantage of the recommended and established cancer screening services at regular intervals, as every tumor detected early can improve the chances of recovery. For more information, contact your health insurance provider or your doctor.
Intended Purpose and Important Information
Ref.-Nr: ZE 002
Intended Purpose
The PanTum Detect® kit is a qualitative immunoassay, intended for in vitro diagnostic use in a clinical laboratory environment. The assay detects Apo10 (DNaseX) and TKTL1 epitopes in monocytes and macrophages from human EDTA whole blood. Elevated levels of these biomarkers are associated with abnormal apoptosis, increased cell proliferation and altered glucose metabolism, which may be indicative of the presence of solid tumors.
The PanTum Detect® kit is intended as an aid in the screening of asymptomatic adults for the possible presence of solid tumors. The test result provides an indication of increased likelihood of solid tumor growth. Test results must be interpreted in conjunction with the individual’s clinical history, epidemiological information and, where appropriate, followed up with further diagnostic investigations such as medical imaging procedures (e.g., PET-CT and/or MRI) for confirmation and localization of potential solid tumor.
Negative test results do not preclude the presence of solid tumors and should not be used as the sole basis for clinical decision-making.
The PanTum Detect® kit is semi-automated and not suitable for self-testing or near-patient testing. The kit is intended for professional use only by laboratory personnel experienced in flow cytometry. Following export from the flow cytometer, the resulting data (fcs file) is uploaded to the ECA portal, where the Zyagnum Analysis Pipeline software visualizes the data through plots and graphics. No automated analysis or interpretation is provided by the ECA portal; all final data analysis and result interpretation are performed manually by qualified personnel.
Contraindications (selection)
Do not use in cases of:
-
- existing or recently treated malignancies
- acute infections or inflammatory conditions
- recent surgery or significant injury
- recent vaccination or contrast agent administration
- immunomodulatory or immunosuppressive therapies
The complete list of contraindications can be found here.
Limitations
-
- Does not identify tumor type or location
- Does not replace established cancer screening programs
- Intended for asymptomatic individuals only
- Negative results do not rule out tumors
- Results must always be interpreted in the full clinical context
Detailed information on the limitations of the method can be found here.
WHERE IS PANTUM DETECT® AVAILABLE?
Germany
PanTum Detect® is currently available as part of the Krebs-Scan program by HanseMerkur:
KREBS-SCAN
ONE TEST FOR ALMOST ALL?
In recent decades, scientists have extensively studied various approaches to improve the early detection of cancer. The most common approach has been to identify tumor-specific materials. This approach was justified by the assumption that different types of cancer have very little in common. However, this meant that each type of cancer required its own tumormarkers, making it an unlikely solution for the early detection of hundreds of different types of cancer.
Now this has changed. Thanks to the discovery of two genes, we are able to understand cancer on a much a deeper level: All types of cancer have two basic biophysical mechanisms in common:
- An impaired apoptosis (programmed cell death).
- A metabolic change, i.e. the way the cancer cells produce energy.
These findings finally paved the way for an early detection method which works for almost all types of cancer. The scientists behind PanTum Detect® use a new approach: scanning the immune system for the two enzymes that identify two basic biophysical mechanisms. Indicators for cancer can thus be detected before it is too late.
The immune system continually combats cancer precursors. When cancer is diagnosed based on symptoms, it usually means that the immune system has been fighting it for many years already.
By analyzing and interpreting the remnants of these battles, PanTum Detect® is able to identify the appropriate moment to seek medical consultation for further diagnostics. Consequently, it has greatly facilitated the early detection of various types of cancer.
STRONG AND EXTENSIVE RESEARCH BASIS
Over the past 25 years, more than 60 scientific papers, publications and studies on TKTL1, DNaseX and EDIM® Technology, the essential components of the PanTum Detect®, have been produced and published in renowned journals such as Science and Nature Communications. These form the basis for the test development of the PanTum Detect® in its current form.
The PanTum Detect® has proven its performance in a large-scale prospective study as well as in several retrospective studies with diagnosed cancer patients.
The following is an excerpt of the performance data of the PanTum Detect® from some clinical studies.
STRONG AND EXTENSIVE RESEARCH BASIS
Over the past 25 years, more than 60 scientific papers, publications and studies on TKTL1, DNaseX and EDIM® Technology, the essential components of the PanTum Detect®, have been produced and published in renowned journals such as Science and Nature Communications. These form the basis for the test development of the PanTum Detect® in its current form.
The PanTum Detect® has proven its performance in a large-scale prospective study as well as in several retrospective studies with diagnosed cancer patients.
The following is an excerpt of the performance data of the PanTum Detect® from some clinical studies.
71.92%
Sensitivity
Proportion of individuals with cancer who were correctly identified as test-positive.
98.89%
Specificity
The proportion of individuals without cancer who were correctly identified as test-negative.
Predictive Values & Accuracy
56.54%
PPV
99.43%
NPV
98.36%
Accuracy
Overall Accuracy: 98.36%
PPV and NPV were calculated based on a cancer prevalence of 1.97% (5-year prevalence in Germany, all age groups; source: Robert Koch Institute Cancer Prevalence Report 2019/2020).
Data Set
4,089
UKE Study
10,246
Routine Diagnostics
14,333
Total Samples
Combined analysis of data from the prospective UKE study and routine diagnostic data.
The performance data cited apply to the intended use of PanTum Detect®: screening asymptomatic adults with normal immune status for the possible presence of solid tumors, regardless of age and gender.
The studies demonstrate PanTum Detect®'s high sensitivity of 71.92% and specificity of 98.89%.
The PanTum Detect® test delivers actionable results with high specificity. Low false-positive rates help minimize unnecessary follow-up diagnostic measures and are essential for meaningful screening of the asymptomatic population.
WHAT ARE SOLID TUMORS?
Cancer occurs when the body’s own cells undergo changes. They no longer perform their intended function, multiply uncontrollably, and invade healthy tissue. This can cause tissues and organs to stop functioning properly.
Many types of cancer initially grow as a lump in a specific area of the body. This is referred to as a solid tumor.
Solid tumors account for about 90% of new cancer cases in adults. They can occur in bones, muscles, organs, or connective tissue. They differ from liquid tumors, where cancer cells circulate through the bloodstream or lymphatic system instead of forming a solid mass. Liquid tumors include leukemias (blood cancer) and some lymphomas (cancers of the lymphatic system).
The PanTum Detect® can detect indications of solid tumors, but not liquid tumors.
